TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| AIDS Budget Faces Reduction New York City's efforts to stem the spread of HIV/AIDS could shrink under the proposed cuts in the city budget, as the total number of new cases of the virus is down from four years ago. online.wsj.com |
Mannkind Corp. Q2 2010 Earnings Call Transcript Mannkind Corp. (MKND) Q2 2010 Earnings Call August 2, 2010; 09:00 am ETComplete Story » seekingalpha.com |
Pfizer's Failure Provides Clarity for ArQule Ohad Hammer submits:Monday Pfizer (PFE) announced that Sutent failed to prolong survival of lung cancer patients when given in combination with Tarceva. The drug led to an increase in progression free survival (PFS), which was the secondary endpoint of the study. The results are not published and there are several open questions such as the extent of PFS improvement, benefit across different subtypes and use of Sutent in patients from the placebo cohort after progressing on Tarceva. Nevertheless, chances to see Sutent+Tarceva as a standard of care for 2nd/3rd line NSCLC are slim.Pfizer’s failure provided some clarity for Arqule (ARQL) and its partner Daiichi Sankyo (DSKYY.PK), who plan to initiate a phase III study for ARQ-197 in combination with Tarceva. The indication Arqule is pursuing is very similar to that pursued by Pfizer, so had the Sutent trial been successful, it would have adversely affected ARQ-197’s prospects in general and potentially the required clinical route.Complete Story » seekingalpha.com |
A Food Fight Over Nutraceuticals Investment U submits: By Tony D’AltorioAt first glance, the food and drug industries have very little in common. One is a relatively slow and safe business, the other a high-risk, high-reward venture. Yet these days, they seem to be moving in a common direction… straight towards the clinical nutrition and nutraceuticals business.Complete Story » seekingalpha.com |
December Will Be Exciting for Up and Coming Corcept Pharmaceuticals Sheff Station submits:In December, the Phase 3 results for Corlux for the treatment of Cushing’s Syndrome are due out and investors have been showing an appetite for the stock as of late. This was evidenced by the unusual volume on Friday, which was a half-day for the equity markets. “Approximately 710,100 shares changed hands, a 970.6 percent increase over its 65-day average volume.” The analyst upgrades have been climbing since start of fall. In August, Global Securities initiated coverage on CORT with a buy rating and $5 price target. On Oct. 29th, Leerink Swann initiated coverage with an Outperform rating. On Nov. 17th, Piper Jaffray initiated coverage of CORT with an Overweight and a $7 target price.Complete Story » seekingalpha.com |